Lung Cancer
Volume 69, Issue 1 , Pages 66-70 , July 2010

Limited contamination in the Dutch–Belgian randomized lung cancer screening trial (NELSON)

  • Eleonora Baecke

      Affiliations

    • Department of Public Health, Erasmus MC – University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • Department of Pulmonology, Erasmus MC – University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author at: Department of Public Health, Room Ae-134, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Tel.: +31 10 7044634.
    • ,
  • Harry J. de Koning

      Affiliations

    • Department of Public Health, Erasmus MC – University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • Suzie J. Otto

      Affiliations

    • Department of Public Health, Erasmus MC – University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • ,
  • Carola A. van Iersel

      Affiliations

    • Department of Public Health, Erasmus MC – University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
    • Department of Pulmonology, Erasmus MC – University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    • Albert Schweitzer Hospital, P.O. Box 444, 3300 AK Dordrecht, The Netherlands
    • ,
  • Rob J. van Klaveren

      Affiliations

    • Department of Pulmonology, Erasmus MC – University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands

Received 24 June 2009 ,Revised 17 August 2009 ,Accepted 19 August 2009.

References 

  1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JWW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–1389
  2. Comprehensive Cancer Centres, the Netherlands. Retrieved from: www.ikcnet.nl, cijfers (18 February 2009).
  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  4. Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer. 2001;31:123–137
  5. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med. 2005;352:2714–2720
  6. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch–Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120(4):868–874
  7. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer. 2003;105:394–399
  8. The Lung Screening Study Research Group. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph, The Lung Screening Study of the National Cancer Institute. Chest. 2004;126:114–121
  9. DANTE Study Group. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180(5):445–453
  10. PLCO Project Team. Mortality results from a randomized prostate cancer screening trial. N Engl J Med. 2009;published March 18 2009 at www.nejm.org
  11. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;published March 18 2009 at www.nejm.org

PII: S0169-5002(09)00476-0

doi: 10.1016/j.lungcan.2009.08.015

Lung Cancer
Volume 69, Issue 1 , Pages 66-70 , July 2010

Article Tools

* Image Usage & Resolution